Melan-A Antibody (M2-7C10): sc-53536

Melan-A Antibody (M2-7C10) is a mouse monoclonal IgG2b antibody that detects Melan-A in human samples through various applications including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and immunohistochemistry. Melan-A, also known as MART-1, is a crucial melanocyte differentiation antigen predominantly expressed in melanomas, melanocyte cell lines, and retinal tissues. Anti-Melan-A antibody (M2-7C10) recognizes peptides presented on the surface of tumor cells, which are targeted by cytotoxic T lymphocytes restricted by HLA-A2. This interaction is vital for the immune system′s ability to identify and eliminate melanoma cells, making Melan-A a promising candidate for antigen-specific immunotherapy in melanoma patients. The ability to generate antimelanoma cytotoxic T lymphocytes using Melan-A peptides underscores its potential in developing targeted cancer treatments. Melan-A monoclonal antibody (M2-7C10) enables researchers to effectively study the expression and function of this important protein, contributing to advancements in melanoma research and therapeutic strategies.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

Melan-A Antibody (M2-7C10) References:

1. Melan-A, a new melanocytic differentiation marker.  |  Busam, KJ. and Jungbluth, AA. 1999. Adv Anat Pathol. 6: 12-8. PMID: 10197235
2. Immunogenicity of nonreplicating recombinant vaccinia expressing HLA-A201 targeted or complete MART-1/Melan-A antigen.  |  Schütz, A., et al. 2001. Cancer Gene Ther. 8: 655-61. PMID: 11593334
3. Improved detection of melanoma antigen-specific T cells expressing low or high levels of CD8 by HLA-A2 tetramers presenting a Melan-A/Mart-1 peptide analogue.  |  Maeurer, MJ., et al. 2002. Int J Cancer. 97: 64-71. PMID: 11774245
4. Expression of Melan-A/MART-1 in primary melanoma cell cultures has prognostic implication in metastatic melanoma patients.  |  Murer, K., et al. 2004. Melanoma Res. 14: 257-62. PMID: 15305155
5. A HLA-DQ5 restricted Melan-A/MART-1 epitope presented by melanoma tumor cells to CD4+ T lymphocytes.  |  Larrieu, P., et al. 2007. Cancer Immunol Immunother. 56: 1565-75. PMID: 17318652
6. PD-1 expression on Melan-A-reactive T cells increases during progression to metastatic disease.  |  Krönig, H., et al. 2012. Int J Cancer. 130: 2327-36. PMID: 21717461
7. Exposure to Melan-A/MART-126-35 tumor epitope specific CD8(+)T cells reveals immune escape by affecting the ubiquitin-proteasome system (UPS).  |  Ebstein, F., et al. 2016. Sci Rep. 6: 25208. PMID: 27143649
8. A quantitative comparison between SOX10 and MART-1 immunostaining to detect melanocytic hyperplasia in chronically sun-damaged skin.  |  Muzumdar, S., et al. 2018. J Cutan Pathol. 45: 263-268. PMID: 29377259
9. Serological analysis of Melan-A(MART-1), a melanocyte-specific protein homogeneously expressed in human melanomas.  |  Chen, YT., et al. 1996. Proc Natl Acad Sci U S A. 93: 5915-9. PMID: 8650193
10. Melan A/MART-1 immunoreactivity in formalin-fixed paraffin-embedded primary and metastatic melanoma: frequency and distribution.  |  Hofbauer, GF., et al. 1998. Melanoma Res. 8: 337-43. PMID: 9764809

The preferred Melan-A antibody is Melan-A Antibody (A103): sc-20032.